To reinforce the relevance of the ER–IGF-1 cross-talk in cancer, microarray data have suggested that a gene signature co-regulated by IGF-1 and estrogens associates with poor prognosis in breast cancer, indicating that the inhibition of both IGF-1R and ER may be necessary in certain subtypes of breast cancer (69). The gene discussed is ESR1; the disease is breast cancer.